Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Bruush Oral Care (BRSH) and Arrive Technology Announce Agreement and Plan of Merger
-
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
-
Bayview Acquisition Corp (BAYAU) Prices 6M Unit IPO at $10/unit
-
Bayview Acquisition Corp Announces Pricing of Upsized $60 Million Initial Public Offering
-
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
-
Coya Therapeutics (COYA) Announces $26.5 Million Private Placement
-
Coya Therapeutics Announces $26.5 Million Private Placement
-
NOVONIX Announces Participation in December Investor Events
-
Global Lights Acquisition Corp Announces the Separate Trading of Its Ordinary Shares and Rights, Commencing on December 4, 2023
-
Chardan Capital Markets Starts Lexeo Therapeutics (LXEO) at Buy
-
Gardiner Healthcare Acquisitions Corp. Announces Intent to Extend
-
Chardan Capital Markets Starts Notable Labs, Inc. (NTBL) at Buy on the 'potential of its proprietary Predictive Precision Medicine Platform'
-
Presto Raises Capital from Remus Investor Group, Announces Addition of Two Board Members, and Significant Cost Reductions
-
Global Lights Acquisition Corp Announces Closing of $69 Million Initial Public Offering
-
VIVOPOWER ANNOUNCES “SUM OF THE PARTS” STRATEGIC VALUE MAXIMISATION REVIEW
-
Global Lights Acquisition Corp (GLACU) Announces Pricing of $60 Million Initial Public Offering
-
Global Lights Acquisition Corp Announces Pricing of $60 Million Initial Public Offering
-
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
-
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million¹
-
Chardan Capital Markets Upgrades ProQR Therapeutics N.V. (PRQR) to Buy
-
ProQR Announces Third Quarter 2023 Operating and Financial Results
-
Lexeo Therapeutics Announces Pricing of Initial Public Offering
-
Abri SPAC I, Inc. Announces Completion of Business Combination
-
Sonnet BioTherapeutics (SONN) Announces Pricing of $4.55 Million Underwritten Public Offering
-
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
-
Gardiner Healthcare Acquisitions Corp. Announces Intent to Extend
-
Notable Labs Closes Merger Transaction With VBL Therapeutics
-
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
-
Myeloid Therapeutics to Participate at Upcoming Investor Conferences
-
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million
-
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
-
Synlogic (SYBX) Prices 7.39M Share Offering at $2.84/sh
-
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
-
Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs
-
Coave Therapeutics to Present at Upcoming Conferences
-
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
-
ARTHEx Biotech to Present at Chardan's 7th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at October Investor Conferences
-
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
-
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
-
Flamingo Therapeutics Announces Participation at Upcoming Investor and Industry Conferences
-
Senti Bio to Participate in Upcoming Conferences
-
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
-
Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
-
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
-
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
-
Locanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
-
Gardiner Healthcare Acquisitions Corp. Announces Intent to Extend
-
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

